U.S. Dermatological Drugs Market Size & Outlook, 2024-2030
U.S. dermatological drugs market, 2018-2030 (US$M)
Related Markets
U.S. dermatological drugs market highlights
- The U.S. dermatological drugs market generated a revenue of USD 8,319.0 million in 2024 and is expected to reach USD 14,484.9 million by 2030.
- The U.S. market is expected to grow at a CAGR of 9.7% from 2025 to 2030.
- In terms of segment, psoriasis was the largest revenue generating therapy in 2024.
- Psoriasis is the most lucrative therapy segment registering the fastest growth during the forecast period.
Dermatological drugs market data book summary
| Market revenue in 2024 | USD 8,319.0 million |
| Market revenue in 2030 | USD 14,484.9 million |
| Growth rate | 9.7% (CAGR from 2025 to 2030) |
| Largest segment | Psoriasis |
| Fastest growing segment | Psoriasis |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Acne, Psoriasis, Rosacea, Alopecia |
Other key industry trends
- In terms of revenue, U.S. accounted for 34.9% of the global dermatological drugs market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. dermatological drugs market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 273.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Dermatological Drugs Market Scope
Dermatological Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. dermatological drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dermatological drugs market will help companies and investors design strategic landscapes.
Psoriasis was the largest segment with a revenue share of 39.49% in 2024. Horizon Databook has segmented the U.S. dermatological drugs market based on acne, psoriasis, rosacea, alopecia covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. dermatology drugs market is experiencing steady growth, fueled by increasing prevalence of chronic skin conditions such as psoriasis, acne, and atopic dermatitis. The rising incidence of these conditions, combined with greater public awareness of skin health, is driving demand for both prescription and over-the-counter dermatological treatments.
The U.S. market is also benefiting from advancements in drug technologies, particularly biologics and targeted therapies, which are significantly improving treatment outcomes for patients with complex and chronic skin disorders. These developments are expected to sustain market growth during the forecast period.
Reasons to subscribe to U.S. dermatological drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. dermatological drugs market databook
-
Our clientele includes a mix of dermatological drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. dermatological drugs market , including forecasts for subscribers. This country databook contains high-level insights into U.S. dermatological drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. dermatological drugs market size, by indication, 2018-2030 (US$M)
U.S. Dermatological Drugs Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
